@nasuspharma: Nasus Pharma announced that abstracts supporting NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, have been accepted for presentation at the upcoming the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, to be held in Phoenix, AZ, November 12-16, 2026.

Nasus Pharma

Open In TikTok:

Region: US

Tuesday 10 November 2026 17:22:27 GMT